• MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board americanpharmaceuticalreview
    August 11, 2021
    MindMed, a biotech company developing psychedelic-inspired therapies, announced the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain.
PharmaSources Customer Service